TECHNICAL NOTE



RF Ablation of Giant Hemangiomas Inducing Acute Renal Failure: A Report of Two Cases

Aukje A. J. M. van Tilborg¹ · Helena F. Dresselaars² · Hester J. Scheffer¹ · Karin Nielsen⁴ · Colin Sietses³ · Petrousjka M. van den Tol⁴ · Martijn R. Meijerink¹

Received: 1 March 2016/Accepted: 25 June 2016/Published online: 7 July 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Objective In patients that require treatment for hepatic giant cavernous hemangiomas (GCH), radiofrequency ablation (RFA) has been suggested to represent a safe and effective alternative to invasive surgery. In a recent report of bipolar RFA, using two expandable needle electrodes, was uneventfully performed in patients with large GCH (>10 cm). The objective of this report is to present two cases in which bipolar RFA of symptomatic GCH was complicated by acute kidney injury.

Materials and methods In 2015 we treated two patients for very large symptomatic GCH (15.7 and 25.0 cm) with bipolar RFA during open laparotomy.

Results In both patients the urine showed a red-brown discoloration directly after the ablation. They became anuric and presented with progressive dyspnea, tachypnea, and tachycardia, requiring hemodialysis for a period of 1 month in one case. Lab results revealed hemepigment-induced acute kidney. Both patients fully recovered and both showed a complete relief of symptoms at 3 months following the procedure.

Conclusion RFA for large GCHs can cause hemepigment-induced acute kidney injury due to massive intravascular

hemolysis. The presented cases suggest that caution is warranted and advocate an upper limit regarding the volume of GCHs that can be safely ablated.

Keywords Radiofrequency ablation · Giant cavernous hemangioma · Hemolysis · Acute kidney injury

Introduction

Hepatic hemangioma is the most frequently encountered solid benign liver tumor. Lesions greater than 5 cm have been referred to as giant cavernous hemangiomas (GCH) [1]. Although most hemangiomas are asymptomatic and are managed safely with observation alone, larger lesions may produce a variety of symptoms and signs, including pain, fullness, nausea, vomiting, and fever. For patients with invalidating symptoms the most renowned treatment remains surgical resection. Unfortunately, surgical resection is associated with morbidity up to 27 % and even a small risk of mortality [2–4]. Although mainly based on small case series and case reports, radiofrequency ablation (RFA) has shown promising results in the recent literature for the less-invasive treatment of relatively small GCH with only minor complications documented [5–13]. In a recent report four patients with symptomatic GCHs measuring >10 cm were uneventfully treated with bipolar RFA [14]. A remarkable volume reduction (58–92 %) coincided with complete (2/4 patients) or considerable (2/4 patients) symptom relief. This case report describes two patients with very large symptomatic GCHs who developed acute kidney injury (AKI) shortly after bipolar RFA, caused by massive heat-induced intravascular hemolysis.

- Departments of Radiology and Nuclear Medicine, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
- Department of Nefrology, VU University Medical Center, Amsterdam, The Netherlands
- Department of Surgical Oncology, Gelderse Vallei Hospital, Ede, Amsterdam, The Netherlands
- VU University Medical Center, Amsterdam, The Netherlands



Aukje A. J. M. van Tilborg a.vantilborg@vumc.nl

Materials and methods

In the following cases a commercially available generator (RF3000, Boston Scientific, USA) was combined with two expandable 7 cm bipolar needle electrodes (InCircle, RF Medical, USA). The procedures were performed using intraoperative ultrasound during open laparotomy under general anesthesia. Ablation protocol was similar to the previously described technique [14].

The local review board waived approval since (1) both the generator and needle electrodes have a CE mark for the ablation of liver tumors, (2) we have a well-documented and transparent prospective registry for all ablations, including our previous experience with RFA for symptomatic GCH, and (3) the multidisciplinary tumor board unanimously agreed on the indication. Patients gave written informed consent and all procedures were conducted according to the guidelines for good clinical practice. Follow-up at 3 months was performed by a contrast-enhanced CT or MRI scan with intravenous contrast. Volume reduction was calculated in percentages and symptom relief was objectified by a visual analogue scale (VAS score).

Results

Case 1

A 52-year-old female, with an otherwise unremarkable history, presented with chronic fatigue and slowly progressing and invalidating pain in the upper right abdominal quadrant. Ultrasound and contrast-enhanced CT revealed the presence of two mating typical GCHs in liver segment VII and VIII (Couinaud) with a diameter of 10 cm and 5.7 cm, respectively of which the combined mass effect distorted the right hemidiaphragm (Fig. 1). The relocated and compressed right liver vein caused hypoperfusion of segment VI on the portal-venous phase CT. Surgical resection would require a portal vein embolization plus right hemihepatectomy. Both the patient and the hepatobiliary surgeon considered the risks associated with such a procedure unacceptable to treat a benign lesion. Initial arterial embolization therapy with polyvinyl alcohol particles was technically successful, but did not lead to any tumor shrinkage or symptomatic relief. Bipolar RFA was performed according to the abovementioned protocol with three overlapping ablations. Directly after the procedure the patient's urine showed a red-brown discoloration. 1 day after the ablation the patient became anuric and subsequently developed pleural effusion with shortness of breath. On physical examination she was tachypnoic and tachycardic without any other abnormalities. Lab results showed AKI (creatinine 446 micromol/l and urea 13.4 mmol/l) and decreased hemoglobin (6.8×10^{4}) . Peripheral blood smear showed fragmentocytes, CPK was 1726 IU/l at peak, and haptoglobin was unmeasurably low (< 0.10 g/l). Urine analysis showed 0-5 leukocytes per high-powered field and >20 erythrocytes per high-powered field (no dysmorphic erythrocytes or casts), with a total urine protein excretion of 0.35 g/day. On abdominal ultrasound the kidneys and urinary tract showed no abnormalities. Blood and urine cultures were negative. There were no indicators of preexisting systemic disease or family history of kidney disease, and the patient received no medication, besides acetaminophen. Autoimmune serology was negative as well as hepatitis B, C, and HIV serology. Because of progressive dyspnea and ongoing anuria haemodialysis through a femoral catheter was started. After 39 days kidney function recovered and dialysis was stopped and the patient was discharged from the hospital 42 days after the procedure. She had a tumor volume reduction of 56 %. The patient reported complete relief of symptoms (VAS score decreased from 6 to 0).

Case 2

A 41-year-old female, with no relevant medical history, suffered from progressive right upper abdominal pain and nausea for which she used morfine and pantoprazole. She had an enlarging GCH with a maximum diameter of 25 cm occupying the right liver lobe (segments V,VI,VII, and VIII) (Fig. 2). A second GCH of 5 cm was located in segment IV. The largest lesion was causing enlargement of the liver and compression of surrounding structures with an ectopic located right kidney. Surgical resection was considered too hazardous because of encasement of the inferior vena cava which would require a venous patch. The multidisciplinary team and the patient made a shared decision to perform RFA for tumor debulking. Bipolar RFA was performed according to the abovementioned protocol using a total of four overlapping ablations plus track ablations. After the procedure the patient was admitted to the intensive care, where reddish-brown urine was noted and urine dipstick turned out positive for hemoglobin. Creatinine levels increased from normal to 184 micromol/l, urea increased to 9,3 mmol/l, CPK increased to 2111 IU/l, and Hb decreased to 5.0×10^{9} /l, indicating that kidney injury was possibly caused by hemolysis. Rhabdomyolysis was too mild to be the cause of the kidney injury. Blood and urine cultures were negative. There were no indicators of preexisting systemic disease and no family history of renovascular disease. Also, no new medication was started. We started a hydration regimen and the patient received one packed cell. The next day






Fig. 1 A 52-year-old female (case 1) with two large mating symptomatic GCHs in segment VII and VIII (Couinaud) of the liver (diameter of 10 and 5.7 cm) before **A** and after **B** bipolar RFA, showing a clear volume reduction. (*Fluid filled space caused by retraction of the tumor.)




Fig. 2 A 41-year-old female (case 2) with a colossal and enlarging GCH occupying all segments of the right liver lobe (maximum diameter 25.0 cm) before **A** and after **B** debulking bipolar RFA, showing a fair volume reduction. (*Fluid filled space caused by retraction of the tumor.)

the patient became hemodynamic and respiratory stable and was dismissed from the intensive care unit. After 8 days all lab results had normalized and the patient was dismissed from the hospital 14 days after the procedure. At 3 months follow-up both tumor shrinking (volume reduction 32 %) and symptom relief (VAS score for symptom assessment decreased from 6 to 0) were considered fair.

Discussion

Hemepigment-induced AKI can either develop from rhabdomyolysis or intravascular hemolysis. The latter is rare and is caused by for example paroxysmal nocturnal hemoglobinuria and G6PD deficiency [15, 16]. The nearly unavoidable hemolysis after RFA, attributable to the

generous blood supply of GCHs, especially for those > 10 cm, is a major drawback. Massive hemolysis can lead to various degrees of hemoglobinuria, hemolytic jaundice, anemia, and renal damage [17]. The development of AKI associated with hepatic RFA has been previously reported in the treatment of liver metastases and hepatocellular carcinoma [18-21]. Also, acute hemolysis secondary to microwave-assisted liver resection and cryoablation has been described [22, 23]. AKI as a result of RFA-induced hemolysis for giant hemangiomas or other benign liver lesions has not been reported before. Our patients developed oliguria that progressed to acute renal failure. The most likely cause of renal failure was hemeinduced nefropathy caused by thermal hemolysis. The postoperative decrease in hemoglobin with fragmentocytes, the unmeasurably low haptoglobin, the postprocedural



positive hemoglobin urine dipstick-test plus the reddishbrown discolored urine all support this etiology.

During RFA, the temperature of the tissue adjacent to the radiofrequency probe reaches temperatures between 50 °C and 100 °C. Red blood cells (RBCs) will undergo budding and fragmentation when exposed to a temperature of >49 °C in vitro [24, 25]. The size of the giant hemangiomas, and hence the size of the ablation zone and length of the procedure, presumably resulted in a more massive thermal hemolysis than that encountered with smaller tumors and shorter procedures.

Hemoglobin is released upon erythrocyte destruction and is filtered by the glomerulus into the urinary space. In the urinary space, hemoglobin is degraded and releases hemepigments which are toxic to the kidney. Hemepigments can cause tubular injury by (1) tubular obstruction, (2) damage due to direct proximal tubular cell injury, and (3) vasoconstriction, resulting in reduced blood flow in the outer medulla [26]. AKI that develops in the setting of hemolysis is rarely an isolated cause. Predisposing conditions, like volume depletion and, possibly, mild ischemia are often present. Volume depletion enhances both vasoconstriction and the formation of obstructing casts, and is of critical importance for the development of heme-induced AKI [27]. Our patients did not experience renal hypoperfusion caused by prolonged hypotension or hypovolemia, and renal toxic drugs like NSAID's or cephalosporins were not administered.

Laparoscopic insufflation can also contribute to intraoperative oliguria due to increased intraabdominal pressure which can lead to decreased renal perfusion and increased renin activity [28]. In both patients the ablation was performed during open surgery, so no laparoscopic insufflation was used.

Although a percutaneous approach generally is less invasive, we preferred an open approach to avoid injury to adjacent organs, to facilitate a more aggressive ablation and to increase precision of needle advancement using intraoperative ultrasound. Moreover, the unusually large needle thickness for the ellipsoid-shaped trocar increases the risk of hemorrhage and bile duct trauma and, in its current form, seems unsuitable for percutaneous use.

In conclusion, we believe that the most likely cause of AKI in our two cases was hemolysis caused by extensive thermal ablation with a bipolar system. Laboratory monitoring after extensive or prolonged radiofrequency liver ablation procedures is recommended for early detection hemolysis. Laboratory values that should be monitored include hemoglobin, creatinine, fragmentocytes, haptoglobin, lactate dehydrogenase, CPK, and urinalysis. In addition, perioperative volume repletion should be warranted, especially if oliguria is noted and/or hemolysis is suspected. When treating large GCH with thermal ablation,

the number of ablations and the duration of the ablation sequences should be reduced to the absolute minimum. For colossal tumors or multiple tumor sites a multistep approach or other treatment options should be considered to prevent hemepigment-induced AKI. The general acceptance of thermal ablation for symptomatic GCHs in routine clinical practice seems precipitated. Given the paucity of patients with an unresectable symptomatic GCH, it may prove difficult to setup larger safety studies. Outside the setting of clinical trials we recommend reticence, especially for GCHs >10 cm.

Compliance with Ethical Standard

Conflicts of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Toro A, Mahfouz AE, Ardiri A, Malaguarnera M, Malaguarnera G, Loria F, et al. What is changing in indications and treatment of hepatic hemangiomas. A Rev Ann Hepatol. 2014;13(4):327–39.
- Lerner SM, Hiatt JR, Salamandra J, Chen PW, Farmer DG, Ghobrial RM, et al. Giant cavernous liver hemangiomas: effect of operative approach on outcome. Arch Surg. 2004;139:818–21.
- 3. Clarke D, Currie E, Madhavan K, Parks R, Garden O. Hepatic resection for benign non-cystic liver lesions. HPB. 2004;6(2):115–9.
- 4. Hoekstra LT, Bieze M, Erdogan D, Roelofs JJ, Beuers UH, van Gulik TM. Management of giant liver hemangiomas: an update. Expert Rev Gastroenterol Hepatol. 2013;7(3):263–8.
- Cui Y, Zhou LY, Dong MK, Wang P, Ji M, Li XO, et al. Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma. World J Gastroenterol. 2003;9(9):2132–4.
- Zagoria RJ, Roth TJ, Levine EA, Kavanagh PV. Radiofrequency ablation of a symptomatic hepatic cavernous hemangioma. AJR Am J Roentgenol. 2004;182(1):210–2.
- Fan RF, Chai FL, He GX, Li RZ, Wan WX, Bai MD, et al. Clinical evaluation of radiofrequency ablation therapy in patients with hepatic cavernous hemangiomas. Zhonghua Yi Xue Za Zhi. 2005;85(23):1608–12.
- 8. Tak WY, Park SY, Jeon SW, Cho CM, Kweon YO, Kim SK, et al. Ultrasonography-guided percutaneous radiofrequency



- ablation for treatment of a huge symptomatic hepatic cavernous hemangioma. Clin Gastroenterol. 2006;40(2):167–70.
- Fan RF, Chai FL, He GX, Wei LX, Li RZ, Wan WX, et al. Laparoscopic radiofrequency ablation of hepatic cavernous hemangioma. a preliminary experience with 27 patients. Surg Endosc. 2006;20(2):281–5.
- Hinshaw JL, Laeseke PJ, Weber SM, Lee FT Jr. Multiple-electrode radiofrequency ablation of symptomatic hepatic cavernous hemangioma. AJR Am J Roentgenol. 2007;189(3):W146–9.
- Park SY, Tak WY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography guided radiofrequency ablation. J Hepatol. 2011;54:559–65.
- Zou H, Yan J, Wu YX, Ou X, Li XW, Xia F, et al. The new technology of enhanced radiofrequency ablation is safe and effective for treating giant hepatic hemangioma. Zhonghua Gan Zang Bing Za Zhi. 2012;20(4):261–5.
- Sharpe EE, Dodd GD. Percutaneous radiofrequency ablation of symptomatic giant hepatic cavernous hemangiomas: report of two cases and review of literature. Vasc Interv Radiol. 2012;23(7): 971–5.
- 14. Meijerink MR, van den Tol P, van Tilborg AA, van Waesberghe JH, Meijer S, van Kuijk C. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. Eur J Radiol. 2011;77(1): 167–71.
- 15. Nair RK, Khaira A, Sharma A, Mahajan S, Dinda AK. Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: report of three cases and a brief review of the literature. Int Urol Nephrol. 2008;40(2):471–5.
- Lau HK, Li CH, Lee AC. Acute massive haemolysis in children with glucose-6-phosphate dehydrogenase deficiency. Hong Kong Med J. 2006;12(2):149–51.
- 17. Gao J, Ke S, Ding XM, Zhou YM, Qian XJ, Sun WB. Radiofrequency ablation for large hepatic hemangiomas: initial experience and lessons. Surgery. 2013;153(1):78–85.

- Keltner JR, Donegan E, Hynson JM, Shapiro WA. Acute renal failure after radiofrequency liver ablation of metastatic carcinoid tumor. Anesth Analg. 2001;93:587–9.
- Fukumori K, Shakado S, Makihata T, Takemoto R, Fukuizumi K, Miyahara T, et al. A case of chronic renal failure caused hyperkalemia following percutaneous radiofrequency ablation therapy for hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi. 2003;100:702–6.
- Tsui SL, Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. Hepatogastroenterology. 2003;50: 526–9
- Li H, Li B, Wei Y, Liu F. Hemolysis as a complication of radiofrequency ablation for hepatocellular carcinoma must be paid more attention. Dig Dis Sci. 2011;56:3391–2.
- 22. Ausania F, Iglesias RC, Rivas MC. Microwave liver ablation and dark urine. Ann R Coll Surg Engl. 2014;96(4):e1–3.
- Kohli V, Clavien PA. Cryoablation of liver tumours. Br J Surg. 1998;85:1171–2.
- Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230(1):1–8.
- Haemolytic Transfusion Reactions. In: Mollison PL, Engelfriet CP, Contreras M, eds. Blood transfusion in clinical medicine. 8th ed. Oxford: Blackwell Scientific, 1987:608.
- Heyman SN, Rosen S, Fuchs S, Epstein FH, Brezis M. Myoglobinuric acute renal failure in the rat: a role for medullary hypoperfusion, hypoxia, and tubular obstruction. J Am Soc Nephrol. 1996;7(7):1066.
- Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996;49(2):314.
- 28. Koivusalo AM, Kellokumpu I, Ristkari S, et al. Splanchnic and renal deterioration during and after laparoscopic cholecystectomy: a comparison of the carbon dioxide pneumoperitoneum and the abdominal wall lift method. Anesth Analg. 1997;85:886–91.

